Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Exopharm. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Exopharm's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Exopharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Exopharm's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Exopharm's earnings growth to the Australia market average as no estimate data is available.
Unable to compare Exopharm's revenue growth to the Australia market average as no estimate data is available.
Unable to determine if Exopharm is high growth as no earnings estimate data is available.
Unable to determine if Exopharm is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Exopharm's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Dr. Ian E. Dixon, PhD, MBA, MAICD, has been an Executive Director at Medigard Limited since November 2017 and has been its Chairman of Scientific and Medical Advisory Panel since December 2017. Dr. Dixon serves as Company Founder, Technology Co-Founder, Managing Director and a Director of Exopharm Limited. Dr. Dixon serves as the Chief Executive Officer and Executive Director of Genscreen Pty Ltd. Dr. Dixon has worked in Australia, Cambridge (UK) and the USA, with extensive business dealings in Asia, Japan and China. He is the founder/co-founder of Okedro Pty Ltd. In 2011, he co-founded Cynata Inc. He co-founded Genscreen Pty Ltd in 2002. From 1987 to 1995, he grew two successful export-oriented manufacturing and R&D businesses - both purchased by public companies. Dr. Dixon ha a track record of building value in innovative medical-relate products and technologies. In 1995, he joined Vision Systems as the Director of the Product Group within the Invetech business unit and managed the team responsible for developing innovative diagnostic, pathology automation and security system products. He is an experienced business-builder and has over 23 years of international experience in the formation and growth of successful businesses and partnerships. He is a Member of a range of International biomedical societies, including the International Society for Cellular Therapy, the International Society for Biological Therapy of Cancer, the International Liposome Society, the International Society for Antiviral Research, the International Society for Stem Cell Research and the International Society for Influenza and other Respiratory Virus Diseases. Dr. Dixon served as the Chairman of Scientific Advisory Board of Cynata Therapeutics Limited (Formerly Eco Quest Limited). He has been an Independent Non-Executive Director of Noxopharm Limited since March 15, 2016. He served as a Director of Cynata Incorporated. He served as a Non-executive Director of Cell Therapies Pty Ltd. He also belongs to the American Australian Association, the Australian Institute of Company Directors, University House (University of Melbourne), Finsia (previously Securities Institute of Australia) and Royal Automotive Club of Victoria. Dr. Dixon served as Chief Executive Officer of Rectifier Technologies Limited until October 13, 2010. He qualified as a mechanical engineer in the early 1980s and then also completed a course in Electronics Engineering. Dr. Dixon holds a PhD in Biomedical Engineering and Bachelor of Engineering from Monash University and an MBA and professional engineering qualifications from Swinburne University.
Ian's compensation has increased whilst company is loss making.
Ian's remuneration is lower than average for companies of similar size in Australia.
COO & Technology Co-Founder
Company Secretary & Non-Executive Director
Chief Commercial Officer
Board of Directors
Company Secretary & Non-Executive Director
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
What Type Of Shareholder Owns Exopharm Limited's (ASX:EX1)?
So it's nice to see some insider ownership, because it may suggest that management is owner-oriented. … Exopharm is a smaller company with a market capitalization of AU$36m, so it may still be flying under the radar of many institutional investors. … institutional investors have not yet purchased much of the company.
Exopharm Limited, a biopharmaceutical company, focuses on developing and commercializing human therapeutics in Australia. The company is Plexaris and Exomere products, including non-clinical, pre-clinical, and clinical testing for other medical conditions, such as dry age-related macular degeneration and osteoarthritis. Exopharm Limited was founded in 2013 and is headquartered in Melbourne, Australia.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.